Science 37, a clinical research organization known for its virtual, decentralized trial system, is planning to go public by merging with a special acquisition company, known as LifeSci Acquisition II Corp.
US-based Science 37 says its Decentralized Clinical Trial Operating System™can enable significantly faster enrollment, retain patients at a meaningfully high rate, and achieve higher enrollment among diverse patient populations. Since its founding in 2014, the company has completed 95 decentralized clinical trials that engaged more than 366,000 patients.
The transaction values Science 37, with 2020 revenue of $24 million, at a total enterprise value of about $1.05 billion. Upon closing of the proposed transaction, the combined company will operate as Science 37 and is expected to be listed on the NASDAQ under the ticker symbol “SNCE.”
With 350 remote employees, Science 37 is one of very few entities that has a unicorn status without any physical offices.
Read the press release